The pharmacology and toxicology of "ecstasy" (MDMA) and related drugs.
暂无分享,去创建一个
[1] E. Ellinwood,et al. Cocaine and other stimulants. Actions, abuse, and treatment. , 1988, The New England journal of medicine.
[2] A. Louis,et al. Cerebral Vasculitis Associated With Cocaine Abuse or Subarachnoid Hemorrhage?-Reply , 1988 .
[3] A. Dinan,et al. 2. Hyperpyrexia Associated with Fatal Paramethoxyamphetamine (PMA) Abuse , 1998 .
[4] Michael J A Parr,et al. Hyponatraemia and death after “ecstasy” ingestion , 1997, The Medical journal of Australia.
[5] A. Alciati,et al. Three cases of delirium after "ecstasy" ingestion. , 1999, Journal of Psychoactive Drugs.
[6] G. Rutty,et al. Deaths associated with MBDB misuse , 2000, International Journal of Legal Medicine.
[7] F. Vollenweider,et al. Psychological and Cardiovascular Effects and Short-Term Sequelae of MDMA (“Ecstasy”) in MDMA-Naïve Healthy Volunteers , 1998, Neuropsychopharmacology.
[8] J. Mørland,et al. Toxicity of drug abuse--amphetamine designer drugs (ecstasy): mental effects and consequences of single dose use. , 2000, Toxicology letters.
[9] J. Henry. Ecstasy and the dance of death. , 1992, BMJ.
[10] R. Veit,et al. Cardiovascular autonomic dysregulation in users of MDMA (“Ecstasy”) , 1998, Psychopharmacology.
[11] A S Christophersen,et al. Amphetamine designer drugs - an overview and epidemiology. , 2000, Toxicology letters.
[12] N. Lavies,et al. An overdose of ecstasy , 1992, Anaesthesia.
[13] A. Cho,et al. Metabolism of methylenedioxymethamphetamine: formation of dihydroxymethamphetamine and a quinone identified as its glutathione adduct. , 1990, The Journal of pharmacology and experimental therapeutics.
[14] J. Rodés,et al. Ecstasy: a common cause of severe acute hepatotoxicity. , 1998, Journal of hepatology.
[15] J. Jaffe,et al. The complications of 'ecstasy' (MDMA) , 1988, JAMA.
[16] A. Parrott. Human Research on MDMA (3,4-Methylene- dioxymethamphetamine) Neurotoxicity: Cognitive and Behavioural Indices of Change , 2000, Neuropsychobiology.
[17] R. Byard,et al. Amphetamine derivative fatalities in South Australia--is "Ecstasy" the culprit? , 1998, The American journal of forensic medicine and pathology.
[18] K. L. Jansen,et al. Ecstasy (MDMA) dependence. , 1999, Drug and alcohol dependence.
[19] M. Morgan. Memory deficits associated with recreational use of “ecstasy” (MDMA) , 1999, Psychopharmacology.
[20] A. Milosevic,et al. The occurrence of toothwear in users of Ecstasy (3,4-methylenedioxymethamphetamine). , 1998, Community dentistry and oral epidemiology.
[21] A. Logan,et al. Survival following ‘Ecstasy’ ingestion with a peak temperature of 42°C , 1993 .
[22] S. Kish,et al. Brief Communications Expedited Publication Striatal serotonin is depleted in brain of a human MDMA (Ecstasy) user , 2000 .
[23] D. Mclellan,et al. Muscle changes in the neuroleptic malignant syndrome , 2000, Journal of clinical pathology.
[24] R. Loveland,et al. Bilateral gluteal compartment syndrome after ‘ecstasy’ hyperpyrexia , 2000, Journal of the Royal Society of Medicine.
[25] Steven B Karch,et al. The pathology of drug abuse , 1993 .
[26] R. Glennon,et al. Initial Characterization of PMMA as a Discriminative Stimulus1 , 1997, Pharmacology Biochemistry and Behavior.
[27] A. Freemont,et al. Ecstasy, 3–4 Methylenedioxymethamphetamine (MDMA), a Fatality Associated with Coagulopathy and Hyperthermia , 1991, Journal of the Royal Society of Medicine.
[28] L. Itti,et al. Effect of ecstasy [3,4-methylenedioxymethamphetamine (MDMA)] on cerebral blood flow: a co-registered SPECT and MRI study , 2000, Psychiatry Research: Neuroimaging.
[29] R O Bost,et al. 3,4-Methylenedioxymethamphetamine (MDMA) and other amphetamine derivatives. , 1988, Journal of forensic sciences.
[30] S. Satchell,et al. Inappropriate antidiuretic hormone secretion and extreme rises in serum creatinine kinase following MDMA ingestion. , 1994, British journal of hospital medicine.
[31] G. Screaton,et al. Hyperpyrexia and rhabdomyolysis after MDMA ("ecstasy") abuse , 1992, The Lancet.
[32] W. Mcglothlin,et al. LSD revisited. A ten-year follow-up of medical LSD use. , 1971, Archives of general psychiatry.
[33] Patrick J. O'Donnell,et al. Level of use of 3,4-methylenedioxymethamphetamine (MDMA or Ecstasy) in humans correlates with EEG power and coherence , 1999, Psychopharmacology.
[34] R. de la Torre,et al. Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans. , 1999, The Journal of pharmacology and experimental therapeutics.
[35] M. Conner,et al. Analysis of illicit ecstasy tablets: implications for clinical management in the accident and emergency department. , 1999, Journal of accident & emergency medicine.
[36] T. Lukaszewski. 3,4-methylenedioxyamphetamine overdose. , 1979, Clinical toxicology.
[37] A. Poklis,et al. Distribution of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) stereoisomers in a fatal poisoning. , 1996, Forensic science international.
[38] J. A. Henry,et al. Subarachnoid haemorrhage associated with MDMA abuse. , 1993, Journal of neurology, neurosurgery, and psychiatry.
[39] F. Peters,et al. Toxicokinetics and analytical toxicology of amphetamine-derived designer drugs ('Ecstasy'). , 2000, Toxicology letters.
[40] A. Poklis,et al. Fatal intoxication from 3,4-methylenedioxyamphetamine. , 1979, Journal of Forensic Sciences.
[41] N. Benowitz,et al. Environmental and drug-induced hyperthermia. Pathophysiology, recognition, and management. , 1984, Emergency medicine clinics of North America.
[42] M. Morgan. Recreational Use of “Ecstasy” (MDMA) Is Associated with Elevated Impulsivity , 1998, Neuropsychopharmacology.
[43] T. Tena,et al. Amphetamine derivative related deaths. , 1997, Forensic science international.
[44] U. McCann,et al. Adverse Reactions with 3,4-Methylenedioxymethamphetamine (MDMA; ‘Ecstasy’) , 1996, Drug safety.
[45] B. Synek,et al. Death from hyponatraemia-induced cerebral oedema associated with MDMA ("Ecstasy") use. , 1999, The New Zealand medical journal.
[46] J. Henry,et al. Fatal interaction between ritonavir and MDMA , 1998, The Lancet.
[47] J. Fisk,et al. Working memory deficits in current and previous users of MDMA ('ecstasy'). , 2000, British journal of psychology.
[48] U. McCann,et al. (±)3,4-Methylenedioxymethamphetamine (‘Ecstasy’)-Induced Serotonin Neurotoxicity: Studies in Animals , 2000, Neuropsychobiology.
[49] B. Rumack,et al. Methylenedioxyamphetamine. Clinical description of overdose, death, and review of pharmacology. , 1981, Archives of internal medicine.
[50] S. Pallanti,et al. MDMA (Ecstasy) precipitation of panic disorder , 1992, Biological Psychiatry.
[51] C. Hyde,et al. ‘Ecstasy’ Psychosis and Flashbacks , 1991, British Journal of Psychiatry.
[52] I. Leopold,et al. Pharmacology and toxicology. , 1951, A.M.A. archives of ophthalmology.
[53] W. Hall,et al. VIEWPOINT Viewpoint , 2022 .
[54] J. Jankovic,et al. Ecstasy intoxication: an overlap between serotonin syndrome and neuroleptic malignant syndrome. , 1996, Clinical neuropharmacology.
[55] R. Bost,et al. 'Eve' and 'Ecstasy'. A report of five deaths associated with the use of MDEA and MDMA. , 1987, JAMA.
[56] L. Mair,et al. An association between the regular use of 3,4 methylenedioxy-methamphetamine (ecstasy) and excessive wear of the teeth. , 1998, Addiction.
[57] Jörg Daumann,et al. High Intensity Dependence of Auditory Evoked Dipole Source Activity Indicates Decreased Serotonergic Activity in Abstinent Ecstasy (MDMA) Users , 2000, Neuropsychopharmacology.
[58] G. Cimbura. 3,4-methylenedioxyamphetamine (MDA): analytical and forensic aspects of fatal poisoning. , 1972, Journal of forensic sciences.
[59] M. Bourin,et al. 3,4-Methylenedioxy analogues of amphetamine: Defining the risks to humans , 1999, Neuroscience & Biobehavioral Reviews.
[60] R. Glennon,et al. MDMA Stimulus Generalization to the 5-HT1A Serotonin Agonist 8-Hydroxy-2- (di-n-propylamino)tetralin , 2000, Pharmacology Biochemistry and Behavior.
[61] M. Polkey,et al. Hyponatraemia and catatonic stupor after taking "ecstasy". , 1993, BMJ.
[62] S. Walton,et al. Cutaneous vasculitis due to ciprofloxacin. , 1992, BMJ.
[63] R. Clark,et al. Drug-induced hyperthermia. , 1997, Critical care clinics.
[64] C. C. Smith,et al. Ecstasy induced hepatitis mimicking viral hepatitis. , 1995, Gut.
[65] R. de Silva,et al. ‘Ecstasy’ and Intracerebral Haemorrhage , 1992, Scottish medical journal.
[66] T. Ernst,et al. Cerebral 1H MRS alterations in recreational 3,4‐methylenedioxymethamphetamine (MDMA, “ecstasy”) users , 1999, Journal of magnetic resonance imaging : JMRI.
[67] I. Sachs,et al. The action of some amines related to adrenaline: methoxy‐phenylisopropylamines , 1939, The Journal of physiology.
[68] M. M. Taylor,et al. Assessment of the MDA and MDMA Optical Isomers in a Stimulant-Hallucinogen Discrimination , 1997, Pharmacology Biochemistry and Behavior.
[69] P. Rothwell,et al. Cerebral venous sinus thrombosis induced by 'ecstasy'. , 1993, Journal of neurology, neurosurgery, and psychiatry.
[70] R. de la Torre,et al. Immunomodulating properties of MDMA alone and in combination with alcohol: a pilot study. , 1999, Life sciences.
[71] J. S. Armstrong,et al. Hepatotoxicity and accelerated fibrosis following 3,4-methylenedioxymetamphetamine ("ecstasy") usage. , 1995, Journal of clinical gastroenterology.
[72] J. Osterloh,et al. Multiple severe complications from recreational ingestion of MDMA ('Ecstasy') , 1987, JAMA.
[73] M. Bohnert,et al. Lethal monointoxication by overdosage of MDEA. , 1998, Forensic science international.
[74] J. Cadet,et al. Invited Review Free radicals and the pathobiology of brain dopamine systems , 1998, Neurochemistry International.
[75] A. Forsyth,et al. Musical preference as an indicator of adolescent drug use. , 1997, Addiction.
[76] J. Catalan,et al. Screening for HIV in pregnancy , 1994, BMJ.
[77] E. Sellers,et al. Interactions of amphetamine analogs with human liver CYP2D6. , 1997, Biochemical pharmacology.
[78] M. D. Schechter. MDMA as a discriminative stimulus: Isomeric comparisons , 1987, Pharmacology Biochemistry and Behavior.
[79] R. K. Siegel,et al. MDMA. Nonmedical use and intoxication. , 1986, Journal of psychoactive drugs.
[80] J. C. Borondo,et al. Intentional overdose and death with 3,4-methylenedioxyethamphetamine (MDEA; "Eve"): case report. , 1998, The American journal of forensic medicine and pathology.
[81] D. Sweeney,et al. ECSTACY: A Review of MDMA and MDA , 1987, International journal of psychiatry in medicine.
[82] Jones,et al. Review article: mechanisms and management of hepatotoxicity in ecstasy (MDMA) and amphetamine intoxications , 1999, Alimentary pharmacology & therapeutics.
[83] J. Coakley,et al. Exertional heat stroke induced by amphetamine analogues , 1993, Anaesthesia.
[84] F. Vollenweider,et al. Acute psychological and physiological effects of MDMA (“Ecstasy”) after haloperidol pretreatment in healthy humans , 2000, European Neuropsychopharmacology.
[85] U. McCann,et al. Memory impairment in abstinent MDMA ("Ecstasy") users , 1998, Neurology.
[86] A. Oyefeso,et al. "Saturday night fever": ecstasy related problems in a London accident and emergency department. , 1998, Journal of accident & emergency medicine.
[87] A. Walubo,et al. Fatal multi-organ failure after suicidal overdose with MDMA, `Ecstasy': case report and review of the literature , 1999, Human & experimental toxicology.
[88] Z. Szabo,et al. Toxicodynamics and long-term toxicity of the recreational drug, 3, 4-methylenedioxymethamphetamine (MDMA, 'Ecstasy'). , 2000, Toxicology letters.
[89] F. Schifano,et al. MDMA ('ecstasy') consumption in the context of polydrug abuse: a report on 150 patients. , 1998, Drug and alcohol dependence.
[90] R. Evans,et al. Intracranial haemorrhage associated with ingestion of 'ecstasy'. , 1993, Archives of emergency medicine.
[91] J. Cocores,et al. Neuropsychiatric manifestations following the use of 3, 4-methylenedioxymethamphetamine (MDMA; “Ecstasy”) , 1997, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[92] Z. Kruk,et al. Direct effects of 3,4‐methylenedioxymethamphetamine (MDMA) on serotonin or dopamine release and uptake in the caudate putamen, nucleus accumbens, substantia nigra pars reticulata, and the dorsal raphé nucleus slices , 2000, Synapse.
[93] C. Long,et al. Traffic fatality related to the use of methylenedioxymethamphetamine. , 1996, Journal of forensic sciences.
[94] R. Riemersma,et al. "Ecstasy" and sudden cardiac death. , 1988, The American journal of forensic medicine and pathology.
[95] R. Cohen. Adverse symptomatology and suicide associated with the use of methylenedioxymethamphetamine (MDMA; “Ecstasy”) , 1996, Biological Psychiatry.
[96] W. van den Brink,et al. Memory disturbances in ”Ecstasy” users are correlated with an altered brain serotonin neurotransmission , 2000, Psychopharmacology.
[97] G. Greer,et al. Subjective reports of the effects of MDMA in a clinical setting. , 1986, Journal of psychoactive drugs.
[98] A. Forrest,et al. A fatal overdose with 3,4-methylenedioxyamphetamine derivatives. , 1994, Forensic science international.
[99] A. Skrondal,et al. Ecstasy and new patterns of drug use: a normal population study. , 1999, Addiction.
[100] S. Dawling,et al. Toxicity and deaths from 3,4-methylenedioxymethamphetamine ("ecstasy") , 1992, The Lancet.
[101] F. Schifano. Potential Human Neurotoxicity of MDMA (‘Ecstasy’): Subjective Self-Reports, Evidence from an Italian Drug Addiction Centre and Clinical Case Studies , 2000, Neuropsychobiology.
[102] Hans Leysieffer,et al. Totally implantable hearing device for sensorineural hearing loss , 1998, The Lancet.
[103] A. Logan,et al. Survival following 'Ecstasy' ingestion with a peak temperature of 42 degrees C. , 1993, Anaesthesia.
[104] S. Peroutka,et al. Subjective effects of 3,4-methylenedioxymethamphetamine in recreational users. , 1988, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.
[105] U. McCann,et al. Lasting neuropsychiatric sequelae of (+-)methylenedioxymethamphetamine ('ecstasy') in recreational users. , 1991, Journal of clinical psychopharmacology.
[106] S. Gore. Fatal uncertainty: death-rate from use of ecstasy or heroin , 1999, The Lancet.
[107] G. Gerra,et al. Serotonergic function after (±)3,4‐methylene-dioxymethamphetarnine (‘Ecstasy’) in humans , 1998, International clinical psychopharmacology.
[108] H. Kalant,et al. Death in amphetamine users: causes and rates. , 1975, Canadian Medical Association journal.
[109] D. Hilton‐Jones,et al. Death after ecstasy ingestion: neuropathological findings. , 1995, Journal of neurology, neurosurgery, and psychiatry.
[110] C. Magee,et al. Hyponatraemia, seizures and stupor associated with ecstasy ingestion in a female. , 1998, Irish medical journal.
[111] A. Hölscher,et al. Liver transplantation for the treatment of fulminant hepatic failure induced by the ingestion of ecstasy , 1997, Transplant international : official journal of the European Society for Organ Transplantation.
[112] G. Hanson,et al. Effects of 3,4-methylenedioxyamphetamine and 3,4-methylenedioxymethamphetamine isomers on central serotonergic, dopaminergic and nigral neurotensin systems of the rat. , 1988, The Journal of pharmacology and experimental therapeutics.
[113] E. Gouzoulis-Mayfrank,et al. Impaired cognitive performance in drug free users of recreational ecstasy (MDMA) , 2000, Journal of neurology, neurosurgery, and psychiatry.
[114] F. Bochner,et al. The agony of “ecstasy” , 1997, The Medical journal of Australia.
[115] C. Humpel,et al. MDMA (‘ecstasy’) enhances basal acetylcholine release in brain slices of the rat striatum , 2000, The European journal of neuroscience.
[116] V. Williams,et al. Ecstasy intoxication: appreciation of complications and the role of dantrolene , 1993, Anaesthesia.
[117] D. E. Cox,et al. "ADAM' or "EVE'?--a toxicological conundrum. , 1996, Forensic science international.
[118] Elie,et al. Auxiliary liver transplantation: Regeneration of the native liver and outcome in 30 patients with fulminant hepatic failure–a multicenter European study , 1996, Hepatology.
[119] M.D.M.A. (“Ecstasy”); a case of possible drug-induced psychosis , 1993, Irish journal of medical science.
[120] R. Schwartz,et al. Accidental ingestion of 'Ecstasy' (3,4-methylenedioxymethylamphetamine). , 1992, Archives of disease in childhood.
[121] R. Cohen. Subjective reports on the effects of the MDMA (‘ecstasy’) experience in humans , 1995, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[122] R. Prouty,et al. Tissue distribution of methylenedioxymethamphetamine. , 1992, Journal of analytical toxicology.
[123] G. Beitia,et al. 3,4-Methylenedioxymethamphetamine (ecstasy)-induced hepatotoxicity: effect on cytosolic calcium signals in isolated hepatocytes. , 1999, Liver.
[124] Y. Shaham,et al. Serotonin Neurotoxicity after (±)3,4-Methylenedioxymethamphetamine (MDMA; “Ecstasy”): A Controlled Study in Humans , 1994, Neuropsychopharmacology.
[125] P D Mueller,et al. Death by "ecstasy": the serotonin syndrome? , 1998, Annals of emergency medicine.
[126] R. D. de Man,et al. [Acute liver failure caused by methylenedioxymethamphetamine ('ecstasy')]. , 1993, Nederlands tijdschrift voor geneeskunde.
[127] Bill Bynum,et al. Ecstasy , 2003, The Lancet.
[128] B. Wilkins. Hyponatraemia must be treated with low water input , 1996, BMJ.
[129] U. Davies,et al. Landmarks for the insertion of oesophageal endoprosthesis. , 1992 .
[130] A. Bodenham,et al. Hyperthermia associated with 3,4‐methylenedioxyethamphetamine (‘Eve’) , 1993, Anaesthesia.
[131] F. X. Vollenweider,et al. Notfälle bei Drogenmissbrauch , 2000, Der Internist.
[132] M. Colado,et al. The acute effect in rats of 3,4-methylenedioxyethamphetamine (MDEA, "eve") on body temperature and long term degeneration of 5-HT neurones in brain: a comparison with MDMA ("ecstasy"). , 1999, Pharmacology & toxicology.
[133] R. de la Torre,et al. Non-linear pharmacokinetics of MDMA ('ecstasy') in humans. , 2000, British journal of clinical pharmacology.
[134] W. Alexander,et al. Hyponatraemia and seizures after ecstasy use , 1999, Postgraduate medical journal.
[135] D. Dietrich,et al. Emotion/cognition-coupling in word recognition memory of depressive patients: an event-related potential study , 2000, Psychiatry Research.
[136] A. Forrest,et al. Pathology of deaths associated with "ecstasy" and "eve" misuse. , 1996, Journal of clinical pathology.
[137] M J Connolly,et al. Cerebral infarction in association with Ecstasy abuse. , 1993, Postgraduate medical journal.
[138] J. Coore,et al. A Fatal Trip with Ecstasy: A Case of 3,4-Methylene-Dioxymethamphetamine/ 3,4-Methylenedioxy-Amphetamine Toxicity , 1996, Journal of the Royal Society of Medicine.
[139] R. Buchert,et al. Ecstasy – long-term effects on the human central nervous system revealed by positron emission tomography , 1999, British Journal of Psychiatry.
[140] A. Schmoldt,et al. Two very different fatal cases associated with the use of methylenedioxyethylamphetamine (MDEA): Eve as deadly as Adam. , 1996, Journal of toxicology. Clinical toxicology.
[141] L. Seiden,et al. Small Changes in Ambient Temperature Cause Large Changes in 3,4-Methylenedioxymethamphetamine (MDMA)-Induced Serotonin Neurotoxicity and Core Body Temperature in the Rat , 1998, The Journal of Neuroscience.
[142] J. Spatt,et al. A pure amnestic syndrome after MDMA ("ecstasy") ingestion. , 1997, Journal of neurology, neurosurgery, and psychiatry.
[143] W. Modell. The Amphetamines: Toxicity and Addiction , 1967 .
[144] B. Schroeder,et al. Bilateral sixth nerve palsy associated with MDMA ("ecstasy") abuse. , 2000, American journal of ophthalmology.
[145] P. McGuire,et al. Diversity of Psychopathology Associated with use of 3,4-Methylenedioxymethamphetamine (‘Ecstasy’) , 1994, British Journal of Psychiatry.
[146] A. Jacks,et al. Retinal haemorrhage caused by “ecstasy” , 1998, British Journal of Ophthalmology.
[147] K. Druschky,et al. Grand-mal-Serie nach Ecstasy-Einnahme , 1999, Der Nervenarzt.
[148] G. Cimbura. PMA deaths in Ontario. , 1974, Canadian Medical Association journal.
[149] R. H. Cravey,et al. A fatal case involving methylenedioxyamphetamine. , 1972, Clinical toxicology.
[150] R. de Silva,et al. Misuse of ecstasy. , 1992, BMJ.
[151] A. Burroughs,et al. Chronic ecstasy (3,4-methylenedioxymetamphetamine) abuse: a recurrent and unpredictable cause of severe acute hepatitis. , 1996, Journal of hepatology.
[152] D. Murphy,et al. Altered neuroendocrine and behavioral responses to m-chlorophenylpiperazine in 3,4-methylenedioxymethamphetamine (MDMA) users , 1999, Psychopharmacology.
[153] B. Kessel. Hyponatraemia after ingestion of “ectasy” , 1994 .
[154] D. N. Sims,et al. Recent paramethoxyamphetamine deaths. , 1998, Journal of analytical toxicology.
[155] A. Shulgin. The background and chemistry of MDMA. , 1986, Journal of psychoactive drugs.
[156] J. Sills,et al. Cerebral oedema after ingestion of MDMA (“ecstasy”) and unrestricted intake of water , 1996, BMJ.
[157] D. Nichols,et al. Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens. , 1986, Journal of psychoactive drugs.
[158] E. Gouzoulis-Mayfrank,et al. [Entactogenic drugs "ecstasy" (MDMA), "eve" (MDE) and other ring-substituted methamphetamine derivatives. A new class of substances among illegal designer drugs?]. , 1996, Der Nervenarzt.
[159] G. D. den Heeten,et al. MDMA ("Ecstasy") and its association with cerebrovascular accidents: preliminary findings. , 2000, AJNR. American journal of neuroradiology.
[160] E. Turillazzi,et al. Adam (MDMA) and Eve (MDEA) misuse: an immunohistochemical study on three fatal cases. , 1999, Forensic science international.
[161] H. Curran,et al. Is MDMA (‘Ecstasy’) Neurotoxic in Humans? An Overview of Evidence and of Methodological Problems in Research , 2000, Neuropsychobiology.
[162] Z. Szabo,et al. Positron emission tomographic evidence of toxic effect of MDMA (“Ecstasy”) on brain serotonin neurons in human beings , 1998, The Lancet.
[163] R. Glennon,et al. Stereochemistry of the metabolism of MDMA to MDA. , 1989, Life sciences.
[164] R. Thomasius,et al. [MDMA ("Ecstasy") use--an overview of psychiatric and medical sequelae]. , 1997, Fortschritte der Neurologie-Psychiatrie.
[165] A. Parrott,et al. Psychobiological problems in heavy 'ecstasy' (MDMA) polydrug users. , 2000, Drug and alcohol dependence.
[166] J. Knochel,et al. Rhabdomyolysis and shock after intravenous amphetamine administration. , 1977, Annals of internal medicine.
[167] F. Vollenweider,et al. Acute Psychological Effects of 3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy”) are Attenuated by the Serotonin Uptake Inhibitor Citalopram , 1999, Neuropsychopharmacology.
[168] S. Hickenbottom,et al. Parkinsonism after taking ecstasy. , 1999, The New England journal of medicine.
[169] M. Ginsberg,et al. Amphetamine intoxication with coagulopathy, hyperthermia, and reversible renal failure. A syndrome resembling heatstroke. , 1970, Annals of internal medicine.
[170] B. Portmann,et al. Acute liver damage and ecstasy ingestion. , 1996, Gut.
[171] U. McCann,et al. (±)3,4-Methylenedioxymethamphetamine (‘Ecstasy’)-Induced Serotonin Neurotoxicity: Clinical Studies , 2000, Neuropsychobiology.
[172] K. Kovar,et al. Screening experiments of ecstasy street samples using near infrared spectroscopy. , 1999, Forensic science international.
[173] R. Holden,et al. Near-fatal hyponatraemic coma due to vasopressin over-secretion after "ecstasy" (3,4-MDMA) , 1996, The Lancet.
[174] A. Parrott,et al. Ecstasy (MDMA) effects upon mood and cognition: before, during and after a Saturday night dance , 1998, Psychopharmacology.
[175] Nicki Bradley. BMJ should use “paracetamol” instead of “acetaminophen” in its index , 1996, BMJ.
[176] Leif Bjermer,et al. Airway hyperresponsiveness to methacholine, adenosine 5-monophosphate, mannitol, eucapnic voluntary hyperpnoea and field exercise challenge in elite cross-country skiers , 2010, British Journal of Sports Medicine.
[177] G. Gerra,et al. Long-lasting effects of (±)3,4-methylene-dioxymethamphetamine (Ecstasy) on serotonin system function in humans , 2000, Biological Psychiatry.
[178] P. McGuire. Long term psychiatric and cognitive effects of MDMA use. , 2000, Toxicology letters.
[179] Klaus P. Ebmeier,et al. Reduced in vivo binding to the serotonin transporter in the cerebral cortex of MDMA (‘ecstasy’) users , 1999, British Journal of Psychiatry.